Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18055001 | 0.88 | AAK1 (0.35) | AAK1CA1CA2CA7HDAC6 | |
| SCHEMBL5567390 | 0.84 | CA1 (0.35) | AAK1CA1CA2CA7HDAC6 | |
| SCHEMBL5567395 | 0.84 | CA1 (0.35) | AAK1CA1CA2CA7HDAC6 | |
| SCHEMBL17157171 | 0.81 | CYP2D6 (0.33) | AAK1CA1CA2CA7HDAC6 | |
| SCHEMBL17157167 | 0.81 | CYP2D6 (0.33) | AAK1CA1CA2CA7HDAC6 | |
| SCHEMBL18055171 | 0.81 | HDAC6 (0.35) | AAK1CA1CA2CA7HDAC6 | |
| SCHEMBL18038885 | 0.79 | AAK1 (0.34) | AAK1CA1CA2CA7HDAC6 | |
| SCHEMBL13489755 | 0.79 | AAK1 (0.34) | AAK1CA1CA2CA7HDAC6 | |
| SCHEMBL23346611 | 0.77 | CA1 (0.34) | AAK1CA1CA2CA7CYP2D6 | |
| SCHEMBL22086927 | 0.77 | CYP2D6 (0.34) | AAK1CA1CA2CA7CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11274124-B2 | Tubulysin analogues as anticancer agents and payloads for antibody-drug conjugates and methods of treatment therewith | WILLIAM MARSH RICE UNIVERSITY (US) | 2022-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274124-B2 | Tubulysin analogues as anticancer agents and payloads for antibody-drug conjugates and methods of treatment therewith | TEK, CD2BP2, SDCBP | AAK1 4475/4885CA1 3161/4885CA2 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.